drugset / Trial / NCT07006792

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

NCT07006792

Phase 4 Active not recruiting 233 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.

Timeline

Start
2025-06-16
Primary completion
2026-05-14
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lebrikizumab Monoclonal antibody Subcutaneous

Indications